Hemoglobin C

If you have West African, Mediterranean, or North African ancestry, or if hemoglobin disease runs in your family, this is a number worth knowing once. Hemoglobin C is one of the most common inherited hemoglobin variants in the world, and whether you carry it shapes your own risk of anemia, your children's risk of sickle cell disease, and how doctors should interpret future blood work.

Most people who carry hemoglobin C feel completely fine. The variant matters most in two situations: when you inherit two copies (causing mild chronic anemia) and when you pair it with sickle hemoglobin (producing hemoglobin SC disease, a major form of sickle cell disease). A single test can tell you which situation, if any, applies to you.

What Hemoglobin C Actually Is

HbC (hemoglobin C) is a structural variant of hemoglobin, the protein inside red blood cells that carries oxygen from your lungs to the rest of your body. It is caused by a single change in the HBB gene on chromosome 11 (glutamic acid is swapped for lysine at position 6 or 7 of the beta-globin chain, depending on numbering convention). It is inherited in an autosomal recessive pattern, meaning you can inherit one copy from one parent (the trait) or one copy from each parent (the disease).

The variant changes how red cells behave. HbC reduces the solubility of hemoglobin inside the cell and can form crystals, making the cells stiffer and shorter-lived than normal. The cells produced are still functional enough to carry oxygen, but they break down faster (a process called hemolysis), and they flow through small blood vessels less smoothly than normal red cells.

What Your Genotype Means

Hemoglobin C testing tells you which of three main inherited patterns you have. Each one carries a very different clinical picture.

Hemoglobin SC Disease

The most clinically important reason to know your HbC status is the possibility of pairing it with sickle hemoglobin (HbS). Together, HbC and HbS produce hemoglobin SC disease, one of the main genotypes recognized as sickle cell disease. People with HbSC face chronic anemia and vaso-occlusive pain crises, though episodes are often less frequent than in HbSS (the most severe form). Specific complications described in the research include aseptic necrosis of long bones, splenic sequestration, and, in some patients, chronic pulmonary problems.

What this means for you: if you are planning a pregnancy with a partner who has sickle cell trait or any other beta-globin variant, knowing your HbC status before conception is far more useful than discovering it after. A child who inherits one HbS allele and one HbC allele will have lifelong sickle cell disease.

Hemoglobin C Disease (HbCC)

If you inherit two copies of HbC, you have hemoglobin C disease. The clinical picture is generally mild compared with sickle cell anemia. Expect chronic low-grade hemolysis, sometimes mild splenomegaly, and modestly altered red cell indices. Blood viscosity tends to run higher than normal because of the abnormal red cell behavior.

Hemoglobin C Trait (HbAC)

Carrying one copy of HbC almost never causes health problems on its own. The trait can subtly alter your red cell indices (sometimes producing slightly lower MCV (mean corpuscular volume, the average size of your red cells) or higher RBC count), but it does not cause anemia or symptoms in most people. Its main importance is genetic. If your partner also carries HbC, HbS, or beta-thalassemia, your children may inherit a more significant blood disorder.

Thrombosis Risk

A 2024 systematic review in the British Journal of Haematology suggests that HbC trait or disease may be a predisposing risk factor for venous and arterial blood clots, with possibly elevated risk during pregnancy. The evidence is largely from case reports and small observational studies, so this finding should be treated as suggestive rather than settled. Still, if you know you carry HbC and you are pregnant, recovering from surgery, or immobilized for any reason, your clinician should factor that into clot-prevention decisions.

Malaria and Inflammation

HbC has been associated with protection against severe malaria, which is one explanation for why it is so common in West Africa. Research also shows that HbC and related genotypes shape the inflammatory response to Plasmodium infection, with distinct patterns of cytokines such as CXCL10, TNF-alpha (tumor necrosis factor alpha, an immune signaling protein), and IL-6 (interleukin 6, another inflammation signal) seen across different hemoglobin genotypes. For someone living in a malaria-endemic area, HbC status is part of the broader picture of infection susceptibility.

How to Read Your Result

Hemoglobin C is reported as a percentage of your total hemoglobin, measured by HPLC (high performance liquid chromatography), capillary electrophoresis, or related methods. The percentage tells you which inherited pattern you have. The exact thresholds vary by laboratory and assay, so compare your results within the same lab over time rather than treating any single cutoff as universal.

Source: percentages are illustrative orientation values consistent with clinical hematology practice and reference platforms (HPLC, capillary electrophoresis) cited in the references. Your lab will likely report the exact fraction, and may use slightly different cutoffs to define each category. Compare results within the same lab when retesting.

When Results Can Be Misleading

A few situations can make a hemoglobin C result harder to interpret. They do not change whether you inherited the variant, but they can affect what your test report shows or how the percentages are quantified.

• Recent blood transfusion: transfused donor blood adds normal HbA to your circulation, diluting the apparent percentage of HbC and other variants for weeks. Repeat testing several months after the last transfusion gives a true reading.
• Co-migration with HbA2 or HbE: on capillary electrophoresis, HbC can run close to HbA2, and on some point-of-care platforms HbC is reported together with HbE and HbA2. Confirmatory testing (HPLC, sometimes DNA sequencing) is used to distinguish them.
• Co-existing iron deficiency or thalassemia: these conditions alter red cell indices independently of HbC and can mask or exaggerate the apparent effect of the variant. Iron studies (ferritin, transferrin saturation) and thalassemia screening help separate these from HbC alone.
• Newborn samples: at birth, fetal hemoglobin (HbF) makes up most of total hemoglobin, so HbC percentages in newborns are smaller than the adult pattern and need age-appropriate interpretation.

Why Repeat Testing Usually Is Not Needed

Hemoglobin C is genetic. Whatever variant you inherited, you carry for life, and the relative percentage stays stable in most people once they reach adulthood. A single high-quality test on an HPLC or capillary electrophoresis platform is usually enough to settle the question. The exception is when the first test is ambiguous, performed shortly after a transfusion, or done on a screening device that groups HbC with HbE and HbA2; in those cases a confirmatory test on a different platform (or DNA-based testing) is the right next step.

What to Do if Your Result Is Positive

Your decision pathway depends on the genotype the test reveals.

• HbAC (trait): no follow-up testing is needed for your own health. The most useful next step is to test your partner if you are planning a pregnancy. If your partner carries HbS, HbC, or beta-thalassemia, see a genetic counselor before conceiving.
• HbCC (disease): confirm the result, then connect with a hematologist. You will likely have a baseline CBC with differential, reticulocyte count, ferritin, and bilirubin to characterize hemolysis. Long-term monitoring is generally light-touch but should include awareness of clot risk during high-risk situations.
• HbSC (compound disease): this is sickle cell disease and warrants ongoing care with a hematologist or sickle cell clinic. Standard workup includes CBC, reticulocyte count, kidney and liver markers, transcranial Doppler in children, and discussion of disease-modifying therapy.
• Ambiguous or unexpected pattern: if your result does not match a clean trait or disease pattern, ask for confirmation by a different method (HPLC if your first test was capillary electrophoresis, or vice versa) and consider DNA-based testing to identify the specific variant.